Fused Tetracyclic Heterocycles from Homoallenylaldazines
FULL PAPER
13C NMR (CDCl3): δ = 15.1, 19.5, 58.6, 74.7, 79.6, 113.0,
138.7 ppm. MS (EI, 70 eV): m/z (%) = 111 (19) [M]+, 110 (38), 98
(17), 83 (31), 55 (52), 43 (100), 42 (57).
1-Methyl-4-{4-[(2-methylprop-1-en-1-yl)oxy]but-2-yn-1-yl}piper-
azine (3f): H NMR (CDCl3): δ = 1.40 (s, 3 H, CH3–C=), 1.45 (s,
3 H, CH3–C =), 2.14 (s, 3 H, CH3–N), 2.2–2.5 (m, 8 H, CH2–CH2),
3.19 (t, J = 1.9 Hz, 2 H, N–CH2–Cϵ), 4.16 (t, J = 1.9 Hz, 2 H, O–
CH2), 5.73 (m, 1 H, CH =) ppm. 13C NMR (CDCl3): δ = 15.0,
19.4, 45.9, 47.0, 51.9, 54.9, 58.8, 80.8, 81.5, 112.3, 138.6 ppm. IR:
1
Preparation of Substituted Ethers 3a–f. General Procedure: Under
argon, an appropriate amine (0.1 mol) was added to a mixture of
CuI (100 mg), paraformaldehyde (3.0 g, equivalent of 0.1 mol
CH2O) and ether 2 (11.0 g, 0.1 mol). The reaction mixture was co-
oled under cold water bath for 10 minutes and then heated at 70 °C
for 30 minutes. The water formed during the reaction was removed
under vacuum and the product was separated by kugelrohr distil-
lation under high vacuum (Ϸ1 Torr). Ethers 3 were produced as
colourless liquids.
ν = 1012, 1145, 1283, 1346, 1455, 1692, 2258 (CϵC), 2765, 2795,
˜
2840, 2934 cm–1. MS (EI, 70 eV): m/z (%) = 224.0 (52) [M + 1]+,
223.0 (100), 221.6 (19), 152.4 (17), 150.9 (91), 112.8 (98), 107.7 (36),
98.9 (41).
Preparation of Homoallenyl Aldehydes 4a–f by Claisen Rearrange-
ment. General Procedure: Ether 3 was heated under argon in an oil
bath preheated to 200 °C for 5–10 minutes. The product, after rapid
cooling in running tap water, was distilled under high vacuum
(Ϸ1 Torr) using a kugelrohr apparatus. Ethers 4 were produced as
colourless liquids.
3-[(Diethylamino)methyl]-2,2-dimethylpenta-3,4-dienal (4a): 1H
NMR (CDCl3): δ = 0.90 (t, J = 7.1 Hz, 6 H, CH3–CH2), 1.13 (s, 6
H, CH3–C–CH3), 2.44 (m, 4 H, CH3–CH2), 2.93 (t, J = 2.0 Hz, 2
H, N–CH2–C=), 4.78 (t, J = 2.0 Hz, 2 H, CH2=), 9.22 (s, 1 H,
CH=O) ppm. 13C NMR (CDCl3): δ = 10.7, 21.4, 45.6, 46.8, 53.9,
N,N-Diethyl-4-[(2-methylprop-1-en-1-yl)oxy]but-2-yn-1-amine (3a):
1H NMR (CDCl3): δ = 0.96 (m, 6 H, CH3–CH2–N), 1.47 (s, 3 H,
CH3–C=), 1.52 (s, 3 H, CH3–C=), 2.44 (m, 4 H, CH3–CH2–N),
3.35 (t, J = 2.0 Hz, 2 H, N–CH2–Cϵ), 4.22 (t, J = 2.0 Hz, 2 H, O–
CH2), 5.80 (m, 1 H, CH=) ppm. 13C NMR (CDCl3): δ = 12.6, 15.0,
19.5, 40.9, 47.2, 58.9, 80.3, 81.5, 112.4, 138.7 ppm. IR: ν = 1016,
˜
1101, 1146, 1321, 1384, 1454, 1693, 2256 (CϵC), 2821, 2927,
2972 cm–1. MS (EI, 70 eV): m/z (%) = 196.9 (38) [M + 2]+, 195.6
(100), 180.4 (30), 125.2 (57), 124.4 (30), 123.8 (73), 122.8 (29), 109.1
(49), 107.9 (31), 86.4 (10), 85.8 (21).
76.7, 105.6, 200.7, 207.7 ppm. IR: ν = 845, 1090, 1387, 1456, 1718
˜
(C=O), 1953 (C=C=C), 2708, 2808, 2933, 2970 cm–1. GC–MS:
m/z (%) = 196.2 (49) [M + 1]+, 167.3 (13), 166.2 (16), 152.1 (11),
86.0 (100).
N,N-Diisopropyl-4-[(2-methylprop-1-en-1-yl)oxy]but-2-yn-1-amine
1
(3b): H NMR (CDCl3): δ = 1.09 (d, J = 6.6 Hz, 12 H, CH3–CH–
CH3), 1.56 (s, 3 H, CH3–C=), 1.61 (s, 3 H, CH3–C=), 3.19 (sept, J
= 6.6 Hz, 2 H, CH3–CH–CH3), 3.46 (t, J = 1.9 Hz, 2 H, N–CH2–
Cϵ), 4.30 (t, J = 1.9 Hz, 2 H, O–CH2), 5.89 (m, 1 H, CH=) ppm.
13C NMR (CDCl3): δ = 15.1, 19.6, 20.7, 34.4, 48.6, 59.3, 79.1, 86.2,
1
3-[(Diisopropylamino)methyl]-2,2-dimethylpenta-3,4-dienal (4b): H
NMR (CDCl3): δ = 0.95 (d, J = 6.7 Hz, 12 H, CH3–CH–CH3),
1.18 (s, 6 H, CH3–C–CH3), 3.05 (sept, J = 6.7 Hz, 2 H, CH3–CH–
CH3), 3.08 (t, J = 2.1 Hz, 2 H, N–CH2–C=), 4.79 (t, J = 2.1 Hz, 2
H, CH2=), 9.32 (s, 1 H, CH=O) ppm. 13C NMR (CDCl3): δ = 20.2,
112.4, 138.9 ppm. IR: ν = 1014, 1144, 1269, 1340, 1383, 1464, 1693,
˜
2256 (CϵC), 2828, 2927, 2966 cm–1. MS (EI, 70 eV): m/z (%) =
225.0 (33) [M + 2] +, 223.7 (76), 152.3 (19), 151.2 (15), 137.2 (17),
136.1 (17), 121.9 (15), 114.0 (8), 109.9 (8).
21.4, 45.2, 47.0, 47.1, 76.6, 106.0, 201.8, 208.5 ppm. IR: ν = 843,
˜
1174, 1363, 1390, 1462, 1720 (C=O), 1952 (C=C=C), 2707, 2834,
2872, 2933, 2966 cm–1.GC–MS: m/z (%) = 224.6 (5) [M + 1]+, 194.6
(8), 180.2 (16), 136.1 (13), 114.1 (100).
2,2-Dimethyl-3-(pyrrolidin-1-ylmethyl)penta-3,4-dienal (4c): 1H
NMR (CDCl3): δ = 1.07 (s, 6 H, CH3–C–CH3), 1.59 (m, 4 H, CH2–
CH2–N), 2.38 (m, 4 H, CH2–CH2–N), 2.95 (t, J = 2.4 Hz, 2 H, N–
CH2–C=), 4.75 (t, J = 2.4 Hz, 2 H, CH2=), 9.13 (1 H, s,
CH=O) ppm. 13C NMR (CDCl3): δ = 21.2, 23.8, 46.8, 53.5, 55.2,
1-{4-[(2-Methylprop-1-en-1-yl)oxy]but-2-yn-1-yl}pyrrolidine (3c): 1H
NMR (CDCl3): δ = 1.47 (s, 3 H, CH3–C=), 1.52 (s, 3 H, CH3–C=),
1.71 (m, 4 H, CH2–CH2–N), 2.52 (m, 4 H, CH2–CH2–N), 3.35 (t,
J = 1.8 Hz, 2 H, N–CH2–Cϵ), 4.23 (t, J = 1.8 Hz, 2 H, O–CH2),
5.81 (m, 1 H, CH=) ppm. 13C NMR (CDCl3): δ = 15.0, 19.5, 23.8,
43.2, 52.5, 58.9, 79.9, 82.5, 112.3, 138.7 ppm. IR: ν = 1014, 1146,
˜
1272, 1322, 1346, 1448, 1693, 2256 (CϵC), 2789, 2910, 2962 cm–1.
MS (EI, 70 eV): m/z (%) = 194.3 (100) [M + 1]+, 192.1 (13), 123.2
(37), 122.2 (40), 121.3 (33), 119.6 (20), 93.6 (16), 84.0 (14).
77.2, 105.8, 200.0, 206.6 ppm. IR: ν = 847, 1142, 1346, 1460, 1716
˜
(C=O), 1954 (C=C=C), 2706, 2796, 2875, 2929, 2968 cm–1. GC–
MS: m/z (%) = 194.2 (17) [M + 1]+, 164.7 (15), 150.1 (8), 84.0 (100).
1-{4-[(2-Methylprop-1-en-1-yl)oxy]but-2-yn-1-yl}piperidine (3d): 1H
NMR (CDCl3): δ = 1.42 (m, 2 H, CH2–CH2–CH2–N), 1.5–1.7 (m,
4 H, CH2–CH2–N), 1.55 (s, 3 H, CH3–C=), 1.60 (s, 3 H, CH3–C=),
2.47 (t, J = 5.1 Hz, 4 H, CH2–CH2–N), 3.28 (t, J = 2.0 Hz, 2 H,
N–CH2–Cϵ), 4.32 (t, J = 2.0 Hz, 2 H, O–CH2), 5.90 (m, 1 H,
CH=) ppm. 13C NMR (CDCl3): δ = 15.1, 19.5, 24.0, 26.0, 48.0,
2,2-Dimethyl-3-(piperidin-1-ylmethyl)penta-3,4-dienal (4d): 1H
NMR (CDCl3): δ = 1.15 (s, 6 H, CH3–C–CH3), 1.3–1.5 (m, 6 H,
CH2–CH2–CH2–N), 2.33 (m, 4 H, CH2–CH2–CH2–N), 2.83 (t, J
= 2.1 Hz, 2 H, N–CH2–C=), 4.80 (t, J = 2.1 Hz, 2 H, CH2=), 9.28
(1 H, s, CH=O) ppm. 13C NMR (CDCl3): δ = 21.4, 24.5, 25.7, 47.0,
54.3, 58.9, 76.8, 105.0, 201.0, 207.4 ppm. IR: ν = 844, 993, 1116,
˜
53.3, 59.0, 80.5, 82.2, 112.4, 138.8 ppm. IR: ν = 1016, 1146, 1340,
˜
1338, 1454, 1716 (C=O), 1954 (C=C=C), 2715, 2796, 2935 cm–1.
1444, 1691, 2256 (CϵC), 2754, 2798, 2854, 2933 cm–1.MS (EI,
70 eV): m/z (%) = 209.6 (13) [M + 2]+, 208.3 (100), 206.2 (15), 137.3
(15), 136.0 (70), 134.0 (14), 108.0 (13), 98.0 (16).
GC–MS: m/z (%) = 208.3 (20) [M + 1]+, 178.2 (11), 98.0 (100).
2,2-Dimethyl-3-(morpholin-4-ylmethyl)penta-3,4-dienal (4e): 1H
NMR (CDCl3): δ = 1.10 (s, 6 H, CH3–C–CH3), 2.36 (t, J = 4.5 Hz,
4 H, N–CH2–CH2–O), 2.84 (t, J = 2.0 Hz, 2 H, N–CH2–C=), 3.52
(t, J = 4.5 Hz, 4 H, N–CH2–CH2–O), 4.77 (t, J = 2.0 Hz, 2 H,
CH2=), 9.27 (1 H, s, CH=O) ppm. 13C NMR (CDCl3): δ = 21.6,
4-{4-[(2-Methylprop-1-en-1-yl)oxy]but-2-yn-1-yl}morpholine
(3e):
1H NMR (CDCl3): δ = 1.53 (s, 3 H, CH3–C=), 1.59 (s, 3 H, CH3–
C=), 2.52 (t, J = 4.7 Hz, 4 H, O–CH2–CH2–N), 3.29 (t, J = 1.8 Hz,
2 H, N–CH2–Cϵ), 3.70 (t, J = 4.7 Hz, 4 H, O–CH2–CH2–N), 4.30
(t, J = 1.8 Hz, 2 H, O–CH2), 5.90 (m, 1 H, CH=) ppm. 13C NMR
(CDCl3): δ = 15.2, 19.6, 47.6, 52.4, 59.0, 67.0, 81.3, 81.4, 112.8,
46.9, 53.1, 58.5, 66.7, 77.0, 103.6, 201.1, 207.7 ppm. IR: ν = 863,
˜
1007, 1116, 1308, 1456, 1716 (C=O), 1954 (C=C=C), 2704, 2810,
2856, 2964 cm–1. GC–MS: m/z (%) = 210.2 (20) [M + 1]+, 181.4
(13), 179.9 (10), 166.1 (14), 122.7 (12), 99.9 (100).
138.8 ppm. IR: ν = 1004, 1117, 1147, 1288, 1346, 1452, 1693, 2256
˜
(CϵC), 2762, 2814, 2856, 2914, 2960 cm–1. MS (EI, 70 eV): m/z
(%) = 211.6 (7) [M + 2]+, 210.3 (95), 139.4 (13), 137.9 (100), 107.9
(20), 100.0 (22).
2,2-Dimethyl-3-[(4-methylpiperazin-1-yl)methyl]penta-3,4-dienal-
1
(4f): H NMR (CDCl3): δ = 1.13 (s, 6 H, CH3–C–CH3), 2.21 (s, 3
Eur. J. Org. Chem. 2005, 2548–2557
© 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2555